CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Dolutegravir / abacavir / lamivudine

Last Updated: July 31, 2014
Result type: Reports
Project Number: SR0387-000
Product Line: Reimbursement Review

Generic Name: Dolutegravir / abacavir / lamivudine

Brand Name: Triumeq

Manufacturer: ViiV Healthcare

Therapeutic Area: HIV Infection

Indications: HIV Infection

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 17, 2015

Recommendation Type: List with criteria/condition